Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Increases By 78.6%

Posted by Tech Dows on Mar 16th, 2025

NeuroMetrix, Inc. (NASDAQ:NURO – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,500 shares, a growth of 78.6% from the February 13th total of 1,400 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 19,700 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research report on Wednesday. They issued a “sell” rating on the stock.

View Our Latest Stock Report on NURO

Hedge Funds Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is currently owned by hedge funds and other institutional investors.

NeuroMetrix Stock Performance

Shares of NASDAQ:NURO remained flat at $4.37 during trading on Friday. The company’s stock had a trading volume of 1,074 shares, compared to its average volume of 13,926. The firm has a market cap of $8.97 million, a P/E ratio of -0.95 and a beta of 2.15. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The firm’s 50-day moving average is $4.26 and its 200 day moving average is $4.10.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.